Eupraxia Pharmaceuticals (EPRX) Cash & Equivalents (2022 - 2026)

Eupraxia Pharmaceuticals (EPRX) has 5 years of Cash & Equivalents data on file, last reported at $58.5 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 113.08% year-over-year to $58.5 million in Q1 2026; TTM through Mar 2026 was $58.5 million, a 113.08% increase from a year earlier, with the FY2025 full-year figure at $80.6 million, up 143.38% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $58.5 million, down from $80.6 million in the prior quarter.
• Over the last five years, Cash & Equivalents for EPRX reached as high as $89.0 million in Q3 2025 and fell as low as $7.4 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $36.6 million across 5 years, with a median of $27.5 million in 2025.
• On a YoY basis, Cash & Equivalents climbed as much as 927.03% in 2025 and fell as far as 23.54% in 2025.
• Year by year, Cash & Equivalents stood at $7.4 million in 2022, then jumped by 160.23% to $19.3 million in 2023, then soared by 71.14% to $33.1 million in 2024, then soared by 143.38% to $80.6 million in 2025, then fell by 27.39% to $58.5 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $58.5 million in Q1 2026, $80.6 million in Q4 2025, and $89.0 million in Q3 2025.